UroGen Pharma Ltd. (URGN) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 13 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026before open 35 8-K
Q2 FY2026Wed, Aug 5, 2026before open 36 8-K
Q1 FY2026Wed, May 6, 2026before open 36 8-K
Q4 FY2025Mon, Mar 2, 2026before open 61 8-K
Q3 FY2025Thu, Nov 6, 2025before open 37 8-K
Q2 FY2025Thu, Aug 7, 2025before open 38 8-K
Q1 FY2025Mon, May 12, 2025before open 42 8-K
Q4 FY2024Mon, Mar 10, 2025before open 69 8-K

What they guided beta

Q3 FY2026 "The patent is expected to provide coverage into July 2044 for ZUSDURI and, if approved, UGN-103, reinforcing the long-term commercial opportunity for the franchise." exhibit
Q3 FY2026 "The ongoing Phase 3 clinical trial evaluating UGN-104 in LG-UTUC is expected to complete enrollment by the end of 2026 or in early 2027." exhibit
Q3 FY2026 "The increase in interest expense was primarily attributable to the additional borrowings of $75.0 million in the first quarter of 2026 in connection with refinancing long-term debt with Pharmakon Advisors, LP, offset by the lower interest rate." exhibit
Q3 FY2026 "2026 JELMYTO Revenue and Company Operating Expense Guidance" exhibit
Q3 FY2026 "UroGen is updating its full-year 2026 net product revenue guidance for JELMYTO to approximately $90 million, compared with its prior guidance range of $97 million to $101 million." exhibit
Q2 FY2026 "Once issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and UGN-103" exhibit
Q2 FY2026 "Continued advancement of pipeline, with UGN-103 on track for NDA submission in the third quarter of 2026 and UGN-501 expected to begin a Phase 1 trial in the fourth quarter of 2026" exhibit
Q2 FY2026 "During the quarter, we strengthened the long-term sustainability of the franchise through a new U.S. patent allowance that, once the patent is issued, is expected to provide intellectual property coverage for both ZUSDURI and UGN-103 into July 2044." exhibit
Q2 FY2026 "Once issued, the patent is expected to provide protection into July 2044, further strengthening the intellectual property supporting ZUSDURI and UGN-103 and reinforcing the long-term commercial opportunity for both products." exhibit
Q2 FY2026 "The Company continues to add new users and remains on track to deliver within its JELMYTO full-year 2026 guidance range of $97 million to $101 million." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/URGN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/URGN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

URGN earnings date badge

HTML

<a href="https://veritasdata.dev/company/URGN/"><img src="https://veritasdata.dev/embed/URGN.svg" alt="URGN earnings date" width="240" height="56"></a>

Markdown

[![URGN earnings date](https://veritasdata.dev/embed/URGN.svg)](https://veritasdata.dev/company/URGN/)

Script

<script async src="https://veritasdata.dev/embed/URGN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/URGN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.